Sterling Capital Management’s Monopar Therapeutics MNPR Stock Holding History
Bought
Maintained
Sold
Other funds holding MNPR
SVCM
SL
Sterling Capital Management's MNPR Position: Q3 2026 in Review
Sterling Capital Management increased its Monopar Therapeutics (MNPR) stake by 44% in Q3 2026, buying an estimated $3.43K and bringing the position to 104 shares worth $8.29K. The position accounts for ﹤0.01% of the portfolio, ranked #2614.
Sterling Capital Management first reported a position in MNPR in Q2 2025 and has held it in 6 quarters since. 106 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.
- Sterling Capital Management held 104 shares of Monopar Therapeutics worth $8.29K as of Q3 2026.
- Sterling Capital Management bought 32 Monopar Therapeutics shares in Q3 2026, an estimated $3.43K.
- Monopar Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2614 holding.
- Sterling Capital Management first reported a position in Monopar Therapeutics in Q2 2025 and has held it in 6 quarters since.
- 106 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.
Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.